Evidence-based medicine versus personalized medicine: Are they enemies?

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 153-164

  De Leon, Jose ^a,b  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CYTOCHROME P450 2D6; DEXAMETHASONE; LITHIUM; NEUROLEPTIC AGENT; PLACEBO; PRESCRIPTION DRUG; RISPERIDONE; VALPROIC ACID;

DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HISTORY OF MEDICINE; HUMAN; MANIA; METHODOLOGY; NORADRENERGIC SYSTEM; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONINERGIC SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS;

EID: 84857852960     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182491383     Document Type: Review

References (148)

1. Feinstein AR. Clinical biostatistics. I. A new name and some other changes of the guard. Clin Pharmacol Ther. 1970;11:135-148.
2. de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol. 2009;29:201-205.
3. Tröhler U. Commentary: 'medical art' versus 'medical science': J Civiale's statistical research on conditions caused by calculi at the Paris Academy of Sciences in 1835. Int J Epidemiol. 2001;30:1252-1253. (Pubitemid 34134267)
4. Grahame-Smith D. Evidence based medicine: Socratic dissent. BMJ. 1995;310:1126-1127.
5. Vandenbroucke JP. Evidence-based medicine and "médecine d'observation." J Clin Epidemiol. 1996;49:1335-1338.
6. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67.
7. Vandenbroucke JP. Clinical investigation in the 20th century: the ascendancy of numerical reasoning. Lancet. 1998;352(suppl 2): SII12-SII16. (Pubitemid 128646431)
8. Buetow S, Getz L, Adams P. Individualized population care: linking personal care to population care in general practice. J Eval Clin Pract. 2008;14:761-766.
9. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006;10:135-151. (Pubitemid 43974591)
10. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
11. Rangachari PK. Evidence-based medicine: old French wine with a new Canadian label? J R Soc Med. 1997;90:280-284. (Pubitemid 27215998)
12. Gerber A, Lungen M, Lauterbach KW. Evidence-based medicine is rooted in Protestant exegesis. Med Hypotheses. 2005;64:1034-1038. (Pubitemid 40385966)
13. Sackett DL. Applying overviews and meta-analyses at the bedside. J Clin Epidemiol. 1995;48:61-66.
14. Cohen L. McMaster's pioneer in evidence-based medicine now spreading his message in England. CMAJ. 1996;154:388-390. (Pubitemid 26057659)
15. Gray GE. Evidence-based medicine: an introduction for psychiatrists. J Psychiatr Pract. 2002;8:5-13.
16. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420-2425.
17. Vandenbroucke JP. 175th anniversary lecture. Medical journals and the shaping of medical knowledge. Lancet. 1998;352:2001-2006.
18. Guyatt G, Cook D, Haynes B. Evidence based medicine has come a long way. BMJ. 2004;329:990-991. (Pubitemid 39486247)
19. Shah HM, Chung KC. Archie Cochrane and his vision for evidence-based medicine. Plast Reconstr Surg. 2009;124:982-988.
20. Jensen UJ. The struggle for clinical authority: shifting ontologies and the politics of evidence. BioSocieties. 2007;2:101-114.
21. Sackett DL, Rosenberg WM. The need for evidence-based medicine. J R Soc Med. 1995;88:620-624.
22. Woolf S. Evidence-based medicine: a historical and international overview. Proc R Coll Physicians Edinb. 2001;31(suppl 9):39-41.
23. Sehon SR, Stanley DE. A philosophical analysis of the evidence-based medicine debate. BMC Health Serv Res. 2003;3:14.
24. Reilly BM. The essence of EBM. BMJ. 2004;329:991-992. (Pubitemid 39486248)
25. Choudry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. Ann Intern Med. 2005;142:260-273. (Pubitemid 40216243)
26. Claridge JA, Fabian TC. History and development of evidence-based medicine. World J Surg. 2005;29:547-553. (Pubitemid 41187386)
27. Feinstein AR. What can clinicians contribute to mutual challenges in medical statistics. J Clin Epidemiol. 1997;103:529-535.
28. Hope T. Evidence based medicine and ethics. J Med Ethics. 1995;21:259-260.
29. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632. (Pubitemid 37430387)
30. de Leon J, Mallory P, Maw L, et al. Lack of replication of the association of low serum cholesterol and suicide attempts in another country opens more questions. Ann Clin Psychiatry. 2011;23:163-170.
31. Knottnerus A, Dinant GJ. Medicine based evidence, a prerequisite for evidence based medicine. BMJ. 1997;315:1109-1110. (Pubitemid 27470305)
32. Susce MT, Villanueva N, Diaz FJ, et al. Obesity and associated complications in patients with severe mental illnesses: a cross sectional survey. J Clin Psychiatry. 2005;66:167-173.
33. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine." Am J Med. 1997;103:529-535.
34. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298:1209-1212. (Pubitemid 47403108)
35. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
36. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168:265-275.
37. Senn SJ. Applying results of randomised trials to patients. N of 1 trials are needed. BMJ. 1998;317:537-538.
38. Senn SJ. Individual therapy: new dawn or false dawn. Drug Inform J. 2001;35:1479-1494.
39. Senn SJ. Author's reply to Walter and Guyatt. Drug Inform J. 2003;37:7-10.
40. Senn S. Individual response to treatment: is it a valid assumption? BMJ. 2004;329:966-968. (Pubitemid 39422915)
41. Senn S, Rolfe K, Julious SA. Investigating variability in patient response to treatmentVa case study from a replicate cross-over study. Stat Methods Med Res. 2011;20(6):657-666.
42. KalowW, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283-289. (Pubitemid 28372321)
43. Kalow W, Endrenyi L, Tang BK. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology. 1999;58:281-284. (Pubitemid 29206182)
44. Ruano G. Quo vadis personalized medicine. Personalized Med. 2004;1:1-7.
45. Meyer UA. PharmacogeneticsVfive decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5:669-676. (Pubitemid 39150124)
46. Caldwell J. Drug metabolism and pharmacogenetics: the British contribution fields of international significance. Br J Pharmacol. 2006;147(suppl):S89-S99. (Pubitemid 43077266)
47. Kalow W. Perspectives in pharmacogenetics. Arch Pathol Lab Med. 2001;125:77-80. (Pubitemid 32096188)
48. Motulsky AG. From pharmacogenetics and ecogenetics to pharmacogenomics. Med Secoli. 2002;14:683-705.
49. Garrod AE. Inborn Errors of Metabolism. London: Oxford University Press; 1909.
50. Vogel F. Moderne probleme der Humangenetik. Ergeb Inn Med Kinderheild. 1959;12:52-125.
51. Fodor SP. Massively parallel genomics. Science. 1997;277:393-395. (Pubitemid 27450716)
52. Pirmohamed M. Pharmacogenetics and pharmacogenomics. J Clin Pharmacol. 2001;52:345-347. (Pubitemid 32939438)
53. Science. New research horizons. Science. 1997;278:2039.
54. Golden F, Lemonick MD. The race is over. Time. July 3, 2000:18-23.
55. Lertola J. Deciphering the code and what might come from it. Time. November 8, 1999:68-69.
56. Collins FS, McKusick VA. Implications of the human genome project for medical science. JAMA. 2001;285:540-544. (Pubitemid 32656320)
57. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008;40:187-224. (Pubitemid 352000946)
58. de Leon J. The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006;6:277-286. (Pubitemid 44174334)
59. de Leon J, Arranz MJ, Ruaño G. Products for pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008;28:599-617.
60. Ioannidis JP. Expectations, validity, and reality in omics. J Clin Epidemiol. 2010;63:945-949.
61. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacol. 2009;34: 159-172.
62. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59:81-89.
63. Lee HK, Lewis LD, Tsongalis GJ, et al. Validation of a CYP2D6 genotyping panel on the NanoChip Molecular BiologyWorkstation. Clin Chem. 2007;53:823-828. (Pubitemid 46744236)
64. Nanosphere, Inc. Nanosphere announces first FDA cleared genetic test for warfarin sensitivity and nanotechnology-based molecular diagnostics platform. September 18, 2007. Available at: http://ir.nanosphere.us/phoenix.zhtml?c= 214748&p=irol-newsArticle&ID=1075936&highlight. Accessed August 8, 2011.
65. de Leon J. The potential of genotyping [letter]. Science. 2008;321:769.
66. Polanyi M. Life's irreducible structure. Science. 1968;160:1308-1312.
67. de Leon J. Future of personalized prescription in psychiatry. In: Schwab M, Kaschka WP, Spina E, eds. Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry 25. Basel, Switzerland: Karger; 2010:118-134.
68. de Leon J. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Curr Drug Met. 2011;12:635-646.
69. de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP 450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14:19-34.
70. Johnson M, Markham-Abedi C, Susce MT, et al. A poor metabolizer for both Cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19): a case report on antidepressant treatment. CNS Spectr. 2006;11:757-760. (Pubitemid 44571740)
71. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;6(suppl 6):4-6. (Pubitemid 30217404)
72. Bertilsson L, Asberg M, Thorén P. Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. Eur J Clin Pharmacol. 1974;7:365-368.
73. Maas JW. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry. 1975;32:1357-1361.
74. Stern SL, Rush AJ, Mendels J. Toward a rational pharmacotherapy of depression. Am J Psychiatry. 1980;137:545-552. (Pubitemid 10107438)
75. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry. 1976;33:1039-1044.
76. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry. 1976;33:1051-1058.
77. The APA Task Force on Laboratory Tests in Psychiatry. The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry. 1987;144:1253-1262.
78. Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA. 1988;259:1699-1702.
79. American Psychiatric Association. Appendix. Practice guideline development process. American Psychiatric Association, 2006. Available at: http://www.psych.org/Departments/QIPS/Downloads/appendix-development%20process- 04-28-06.aspx. Accessed August 15, 2011.
80. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:1317-1324. (Pubitemid 47358167)
81. Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendationsVready for clinical practice? Nat Rev Drug Discov. 2005;4:639-647. (Pubitemid 41149757)
82. Stingl JC, Brockmö ller J. Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther. 2011;89:198-209.
83. Ozdemir V, Aklillu E, Mee S, et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006;7:119-133. (Pubitemid 43263252)
84. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics. 2006;7:889-908. (Pubitemid 44446737)
85. Rahmio?lu N, Ahmadi KR. Classical twin design in modern pharmacogenomics studies. Pharmacogenomics. 2010;11:215-226.
86. Tan Q, Ohm Kyvik K, Kruse TA, et al. Dissecting complex phenotypes using the genomics of twins. Funct Integr Genomics. 2010;10: 321-327.
87. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41:535-552. (Pubitemid 19102462)
88. Angst MS, Phillips NG, Drover DR, et al. Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet. 2010;13:412-425.
89. Birkenfeld AL, Jordan J, Hofmann U, et al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther. 2009;86:605-608.
90. Ozdemir V, Kalow W, Tothfalusi L, et al. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics Person Med. 2005;3:53-71. (Pubitemid 40352699)
91. Dorne JL. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol. 2004;18:609-620. (Pubitemid 39564260)
92. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet. 1999;353:743-746. (Pubitemid 29103819)
93. Hampton JR. Evidence-based medicine, opinion-based medicine, and real-world medicine. Perspect Biol Med. 2002;45:549-568. (Pubitemid 35346232)
94. Smith GD, Egger M. Incommunicable knowledge? Interpreting and applying the results of clinical trials and meta-analyses. J Clin Epidemiol. 1998;51:289-295. (Pubitemid 28156044)
95. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141-147. (Pubitemid 36177237)
96. de Leon J, Bork JA. Risperidone and the cytochrome P4503A [letter]. J Clin Psychiatry. 1997;58:450.
97. Bork J, Rogers T, Wedlund P, et al. A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J Clin Psychiatry. 1999;60:469-476. (Pubitemid 29369803)
98. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485. (Pubitemid 30622123)
99. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151. (Pubitemid 29142884)
100. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29:1263-1268. (Pubitemid 32896574)
101. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59-67.
102. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. (Pubitemid 38903502)
103. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008;83:781-787. (Pubitemid 351556025)
104. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byteVan update of guidelines. Clin Pharmacol Ther. 2011;89:662-673.
105. Altar CA, Amakye D, Bounos D, et al. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin Pharmacol Ther. 2008;83:368-371.
106. Vandenbroucke JP. Observational research, randomised trials and two views of medical science. PLoS Med. 2008;5:339-343.
107. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ. 2006;174:645-646. (Pubitemid 43341875)
108. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417-2419.
109. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134:330-334. (Pubitemid 32163956)
110. Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169:1737-1739.
111. Issa AM, Phillips KA, Van Bebber S, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007;2:177-185. (Pubitemid 47578123)
112. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661-687. (Pubitemid 40143102)
113. Cartwright N. Are RCTs the gold standard. BioSocieties. 2007;2:11-20.
114. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124.
115. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218-228. (Pubitemid 41043792)
116. Young NS, Ioannidis JP, Al-Ubaydli O. Why current publication practices may distort science. PLoS Med. 2008;5:e201.
117. Vandenbroucke JP, de Craen AJM. Alternative medicine: a "mirror image" for scientific reasoning in conventional medicine. Ann Intern Med. 2001;135:507-513. (Pubitemid 32923568)
118. Senn SJ. Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol. 2009;9:10.
119. Feist GJ. The Psychology of Science and the Origins of the Scientific Mind. New Haven, CT: Yale University Press; 2006.
120. Matchar DB, Thakur ME, Grossman I, et al. Testing for Cytochrome P450 Polymorphisms in Adults With Non-psychotic Depression Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. (Prepared by the Duke Evidence-based Practice Center Under Contract No. 290-02-0025.) AHRQ Publication No. 07-E002. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
121. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819-825.
122. Teagarden JR. Warfarin and pharmacogenomic testing: what would Pascal do? Pharmacotherapy. 2009;29:245-247.
123. Pierce CS. Essays in the Philosophy of Science. New York: The Liberal Art Press; 1957.
124. Haack S. Trial and error: the Supreme Court's philosophy of science. Am J Public Health. 2005;95:S66-S73. (Pubitemid 41033421)
125. Polanyi M. Personal Knowledge: Towards a Post-critical Philosophy. Chicago, IL: The University of Chicago Press; 1962.
126. Koshland DE. The cha-cha-cha theory of scientific discovery. Science. 2007;317:761-762.
127. Moonesinghe R, Khoury MJ, Janssens AC. Most published research findings are false-but a little replication goes a long way. PLoS Med. 2007;4:e28.
128. Naylor CD. Grey zones of clinical practice: some limits to evidence-based medicine. Lancet. 1995;345:840-842.
129. Waldrop M. Complexity: The Emerging Science at the Edge of Order and Chaos. New York: Touchstone Books; 1992.
130. Mitchell M. Complexity: A Guided Tour. New York: Oxford University Press; 2009.
131. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56-68.
132. McEachin RC, Saccone NL, Saccone SF, et al. Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med Genet. 2010;11:14.
133. Lee SSJ. Defining statistical race and phenotypic race and their implications for health disparities. Curr Pharmacogenomics Person Med. 2009;7:238-242.
134. Baye TM. Inter-chromosomal variation in the pattern of human population genetic structure. Hum Genomics. 2011;5:220-240.
135. Badcott D. Scientific contribution. Some causal limitations of pharmacogenetic concepts. Med Health Care Philos. 2006;9:307-316.
136. Chakraborty B. Dynamic treatment regimes for managing chronic health conditions: a statistical perspective. Am J Public Health. 2011;101:40-45.
137. Bereiter C, Scardamalia M. Surpassing Ourselves. An Inquiry in to the Nature and Implications Expertise. Chicago and La Salle, IL: Open Court; 1993.
138. Berrios GE, Markova IS. Conceptual issues. In: D'haenen H, den Boer JA, Willner P, eds. Biological Psychiatry. Chichester, UK: John Wiley & Sons, Ltd; 2002:1-24.
139. Hirsch JE. An index to quantify an individual's scientific research output. PNAS. 2005;102:16569-16572. (Pubitemid 41688817)
140. Goldman GM. The tacit dimension of clinical judgment. Yale J Biol Med. 1990;63:47-61. (Pubitemid 20186952)
141. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics. 2010;28:905-913.
142. de Leon J, Greenlee B, Barber J, et al. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30:613-669.
143. Garber AM, Tunis SR. Does comparative-effectiveness research threaten PM? N Engl J Med. 2009;360:1925-1927.
144. Frueh FW. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics. 2009;10:1077-1081.
145. Khoury MJ, Rich EC, Randhawa G, et al. Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Genet Med. 2009;11:707-711.
146. Woodcock J. The human genome and translational research: how much evidence is enough? Health Aff. 2008;27:1616-1618.
147. Miles A, Loughlin M, Polychronis A. Evidence-based healthcare, clinical knowledge and the rise of personalised medicine. J Eval Clin Pract. 2008;14:621-649.
148. Haynes B. ACP Journal Club. Editorial: new and underutilized features of ACP Journal Club PLUS and ACPJC.org: stellar articles, searches, and succinct synopses of the principles and practice of "personalized" evidence-based medicine. Ann Intern Med. 2009;151:JC6-2-JC6-3.